Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology's stock has experienced significant volatility over the past six months. The stock lost -1.03% in the past five trading days, with a drawdown of -13.62% for that period. The share price declined by 67.86% from February 6, 2025, to February 5, 2026. Key events impacting the stock include earnings reports, clinical trial updates, leadership changes, analyst activity, and a prior data delay. The company reported mixed earnings results, with some quarters beating estimates and others missing. A positive update from the Phase 2 trial of Onvansertib initially caused the stock to tumble, and a leadership reshuffle further impacted the stock price. Analyst activity and increased short interest also influenced the stock's performance.

As a clinical-stage biotechnology company, Cardiff Oncology, Inc. is primarily focused on the discovery, development, and commercialization of novel therapies. There is no readily available information indicating demand seasonality for its products and services, as product sales are not yet a significant revenue driver.

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company focused on developing novel cancer therapies using PLK1 inhibition. Their primary product candidate, Onvansertib, is being evaluated in clinical programs for various cancer indications in combination with standard-of-care therapeutics.

Cardiff Oncology, Inc. operates exclusively within the United States.

Cardiff Oncology holds a "Moderate Buy" consensus rating from analysts, with an average price target suggesting a potential upside. MarketBeat ranked Cardiff Oncology higher than 48% of companies in the medical sector. While a positive update from the Phase 2 trial of Onvansertib occurred, the stock experienced a tumble following the news. Concerns exist regarding the efficacy of Onvansertib, with overall response rates reportedly dropping compared to the standard of care.

Cardiff Oncology, Inc. has a mixed ownership structure. Institutional investors hold approximately 16.74% to 37.62% of the company's stock, with major holders including BlackRock, Inc., Vanguard Group Inc, and Laurion Capital Management LP. Individual investors hold the majority stake, around 60% of the company. Insiders own approximately 4.37% of the stock.